CSIMarket
 
Dbv Technologies S a   (DBVT)
Other Ticker:  
 
 
Price: $0.7900 $-0.02 -2.817%
Day's High: $0.819 Week Perf: -7.06 %
Day's Low: $ 0.78 30 Day Perf: -7.06 %
Volume (M): 76 52 Wk High: $ 2.37
Volume (M$): $ 60 52 Wk Avg: $1.33
Open: $0.79 52 Wk Low: $0.65



 Market Capitalization (Millions $) 76
 Shares Outstanding (Millions) 96
 Employees -
 Revenues (TTM) (Millions $) 16
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) -68
 Capital Exp. (TTM) (Millions $) 1

Dbv Technologies S A
Dbv Technologies S.A. is a biopharmaceutical company that specializes in developing immunotherapy treatments for various allergic diseases. The company is based in France and was founded in 2002.

Dbv Technologies is known for its innovative approach to treating allergies, particularly through its Viaskin' platform. This platform utilizes epicutaneous immunotherapy (EPIT) to deliver allergens to patients through a patch worn on the skin. By gradually exposing the immune system to small doses of allergens, the company aims to desensitize patients and reduce allergic responses.

The company's lead product, Viaskin Peanut, is currently under development for the treatment of peanut allergies, which is a common and potentially life-threatening allergy. Dbv Technologies has conducted clinical trials to assess the efficacy and safety of Viaskin Peanut, and the results have been promising. If approved, Viaskin Peanut could become a significant breakthrough in the treatment of peanut allergies.

Dbv Technologies is also investigating potential applications of its Viaskin platform for other allergens, including milk, eggs, and other food allergies. The company has ongoing research and development efforts to expand its product portfolio and address unmet medical needs in the field of allergies.

In summary, Dbv Technologies S.A. is a biopharmaceutical company focused on developing immunotherapy treatments for allergies. Through its Viaskin platform, the company aims to revolutionize the treatment options for patients suffering from allergic diseases, potentially improving their quality of life.


   Company Address: 177-181 avenue Pierre Brossolette Montrouge 92120
   Company Phone Number: 1 55 42 78 78   Stock Exchange / Ticker: NASDAQ DBVT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Dbv Technologies S A

DBV Technologies S.A. Shows Impressive Revenue Growth in Recent Financial Report



DBV Technologies, a biotechnology and pharmaceutical company, recently released its financial results for the October to December 31, 2023 interval. The figures reveal a combination of positive and negative trends that question the company's potential trajectory. This article aims to interpret these results and evaluate their possible impact on DBV Technologies going forward.
Revenue Growth and Decreasing Deficit:
DBV Technologies reported a significant increase in revenue, reaching $8.874 million in the October to December 2023 interval, representing a 224.69% growth compared to the previous year's revenue of $4.84 million. This growth demonstrates the company's ability to generate more income, possibly due to successful product launches, increased market demand, or expanded partnerships.

Dbv Technologies S A

Headline: DBV Technologies Achieves Remarkable Revenue Growth, Outperforming Expectations in the Financial Period Concluding on September 30th, 2023

/>DBV Technologies S.A., a leading player in the biotechnology and pharmaceuticals industry, has recently released its financial results for the July to September 2023 financial period. A closer look at the numbers reveals several positive trends and achievements, despite some challenges that the company faced during this period.
Positive Earnings and Revenue Growth:
One of the highlights of DBV Technologies' financial results is the decrease in loss per share compared to the previous year. The company managed to reduce its loss per share from $-0.18 to $-0.17, indicating progress in managing its costs and improving its financial position. Furthermore, the income per share increased from $-0.26 to $-0.17, indicating a positive shift in DBV Technologies' ability to generate income.

Dbv Technologies S A

DBV Technologies S A Reports Significant Top-Line Growth Amidst Industry Decline in Latest Fiscal Period

Investors in the stock market are always on the lookout for promising opportunities, and one company that deserves attention is DBV Technologies S.A., a Biotechnology & Pharmaceuticals company. Despite facing challenges in the most recent fiscal period, DBV Technologies has shown incredible resilience and potential for growth.
In the previous fiscal period, DBV Technologies encountered a loss of $0.26 per share. However, the company's revenue witnessed an impressive surge of 49.64%, reaching $2.29 million compared to the previous year. This surge showcases DBV Technologies' ability to withstand the downward trend seen in the Biotechnology & Pharmaceuticals sector, which experienced a significant decline in revenues across the board.

Dbv Technologies S A

DBV Technologies S.A. Successfully Reduces Losses and Revenue Decline in Q1 2023

DBV Technologies S.A., a biopharmaceutical company, has announced its financial results for the first quarter of 2023. The company managed to slice its losses on dwindling revenue, with a shortfall per share of $-0.22 compared to $-0.30 in the same reporting period a year before. The revenue decreased by -13.826% to $2.19 million compared to $2.55 million in the same period a year before. However, the earnings per share improved from $-0.51 per share and revenue increased from $0.00 million from the previous times.
Despite these improvements, the net shortfall of the company for the first quarter of 2023 was $-20.561 million, which is larger than the $-16.706 million that was reported in the same period a year ago. Nevertheless, the management at DBV Technologies S.A. has remained upbeat and optimistic about the future.






 

Dbv Technologies S A's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Dbv Technologies S A does not provide revenue guidance.

Earnings Outlook
Dbv Technologies S a does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com